SQUAWK/NEWS
Account
Theme
Account
Menu
Live NewsCategoriesequity

Palvella Therapeutics, Inc. (PVLA) News

Follow Palvella Therapeutics, Inc. (PVLA) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 24 public stories across 12 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.

Symbol PVLA Asset equity Sector Markets 90 days 18 Last 143.08 Updated Nov 05, 2026, 03:56 PM UTC Open live news feed Open PVLA chart & news
M Palvella Therapeutics Reports Quarterly Results Palvella Therapeutics reported results for the quarter ended September 30; no figures were provided. EQUITY | Nov 05, 2026, 03:56 PM UTC M Palvella Therapeutics Shares Drop 1.7% After Q3 Loss Widens Palvella Therapeutics shares fell 1.7% in morning trading after its third-quarter net loss widened. EQUITY | Nov 05, 2026, 03:29 PM UTC M Palvella Therapeutics Q3 2026 Earnings Call Begins Palvella Therapeutics' quarterly earnings call has begun. EQUITY | Nov 05, 2026, 01:27 PM UTC M Palvella Therapeutics Posts Q3 Loss of $1.70 a Share EQUITY | Nov 05, 2026, 01:11 PM UTC M Palvella Therapeutics reports Q3 results Palvella Therapeutics reported a quarterly loss, according to the headline and available body fragment. EQUITY | Nov 05, 2026, 12:49 PM UTC M Palvella Therapeutics Reports Q3 Results; FDA Accepts QTORIN NDA Palvella Therapeutics said the FDA accepted its NDA for QTORIN™ Rapamycin and granted priority review for microcystic lymphatic malformation. EQUITY | Nov 05, 2026, 12:33 PM UTC M Palvella Therapeutics Schedules Q3 2026 Results Call for November 5 EQUITY | Oct 29, 2026, 11:33 AM UTC L FDA Grants Priority Review to Palvella Therapeutics’ Qtorin Palvella Therapeutics said the FDA granted priority review to Qtorin, which the company says could become the first FDA-approved therapy for microcystic lymphatic malformations. REGULATION | Oct 28, 2026, 06:41 PM UTC M FDA Accepts Palvella’s QTORIN NDA for Priority Review The FDA set February 28, 2027, as the PDUFA target action date for QTORIN rapamycin. REGULATION | Oct 28, 2026, 11:34 AM UTC L Palvella Therapeutics, Inc. (PVLA) Gets More FDA Orphan Funding; NDA Filed for QTORIN Palvella received a third year of FDA Orphan Products grant funding supporting its Phase 3 SELVA program for QTORIN rapamycin. The NDA has been completed following positive Phase 3 results; potential U.S. launch in H1 20 REGULATION | Sep 28, 2026, 11:32 AM UTC L U.S. Food and Drug Administration Awards Additional Funding for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations NDA submission completed following positive Phase 3 SELVA results; potential U.S. commercial launch in the first half of 2027, if approvedQTORIN™ rapamycin has the potential to become the first FDA-approved therapy and e REGULATION | Sep 28, 2026, 11:32 AM UTC L PVLA: NDA for QTORIN rapamycin submitted; commercial launch and pipeline expansion expected next year Focused on first-in-disease therapies for rare skin and vascular diseases, the company has submitted an NDA for QTORIN rapamycin and is advancing multiple clinical programs with strong FDA support. Launch planning is rob REGULATION | Sep 15, 2026, 05:02 PM UTC M PVLA files NDA for QTORIN microLM; FDA approval expected in 2027 PVLA advanced its QTORIN platform for rare skin and vascular diseases, filing a lead NDA for microLM and anticipating FDA approval in 2027. The company cites strong IP, regulatory exclusivity and clinical data. REGULATION | Sep 09, 2026, 06:52 PM UTC L Palvella Therapeutics names James R. Treat as Chief Medical Officer Palvella Therapeutics appointed James R. Treat, M.D., a pediatric dermatologist, as Chief Medical Officer, citing expertise in cutaneous vascular anomalies and nearly 20 years of clinical, research and academic experienc EQUITY | Sep 09, 2026, 11:32 AM UTC L Palvella Therapeutics appoints James R. Treat as Chief Medical Officer Palvella Therapeutics appointed James R. Treat as Chief Medical Officer. EQUITY | Sep 09, 2026, 11:30 AM UTC L PVLA appoints James R. Treat as Chief Medical Officer PVLA appointed James R. Treat, M.D., as Chief Medical Officer. EQUITY | Sep 09, 2026, 11:30 AM UTC L Palvella Therapeutics to participate in upcoming healthcare investor conferences Palvella Therapeutics, Inc. said it will participate in upcoming healthcare investor conferences, according to a Globe Newswire announcement. EQUITY | Sep 02, 2026, 11:37 AM UTC L PVLA - Palvella Therapeutics to Participate in Upcoming Healthcare Investor Conferences PVLA - Palvella Therapeutics to Participate in Upcoming Healthcare Investor Conferences EQUITY | Sep 02, 2026, 11:30 AM UTC L PVLA - Palvella Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update PVLA - Palvella Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update EARNINGS | Aug 04, 2026, 11:30 AM UTC L PVLA - Palvella Therapeutics Chief Scientific Officer Jeff Martini, Ph.D. Selected to Present at Upcoming FDA Public Workshop on Drug Repurp PVLA - Palvella Therapeutics Chief Scientific Officer Jeff Martini, Ph.D. Selected to Present at Upcoming FDA Public Workshop on Drug Repurposing REGULATION | Jul 30, 2026, 11:30 AM UTC L H.C. Wainwright says Palvella selloff 'an overreaction' to FDA's BTD denial H.C. Wainwright notes... EQUITY | Jul 21, 2026, 05:12 PM UTC M Palvella Therapeutics Submits First Module Of Rolling NDA To FDA Seeking Approval Of QTORIN 3.9% Rapamycin Anhydrous Gel For Treatment Of Mi Palvella Therapeutics submits first module of rolling NDA to FDA for QTORIN 3.9% rapamycin anhydrous gel approval REGULATION | Jun 29, 2026, 11:33 AM UTC M PVLA: FDA Starts Review Palvella Therapeutics announces FDA rolling review of its new drug application for Qtorin Rapamycin EQUITY | Jun 22, 2026, 11:41 AM UTC H PVLA: FDA Grants Rolling Review Palvella's QTORIN Rapamycin NDA for Microcystic Lymphatic Malformations receives rolling review from FDA EQUITY | Jun 22, 2026, 11:30 AM UTC